Business
Aeterna Zentaris Selects Charleston, S.C. as New Location for its North American Business and Global Commercial Operations
QUÉBEC CITY, May 5, 2014 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:&#...
About this update from Cosciens Biopharma Inc.
[{"type":"text","content":"\n\n\nQUÉBEC CITY, May 5, 2014 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\"), a specialty biopharmaceutical company\n engaged in developing novel treatments in oncology and endocrinology,\n today announced that it has selected Charleston, South Carolina as its\n new location for the Company's North American business and global\n commercial operations. Over the next five years, Aeterna Zentaris is\n expected to implement a staff to support the areas of commercial\n operations, business development, regulatory and quality assurance,\n manufacturing management, clinical and product development, as well as\n various administrative functions. In conjunction with the Company's\n plans and commitment to this investment, the Coordinating Council for\n Economic Development of South Carolina has approved job development\n credits to Aeterna Zentaris.\n\n\nDavid Dodd, President and CEO at Aeterna Zentaris commented, \"The\n Charleston, South Carolina area is one of the most thriving and\n exciting business communities in the United States and we are very much\n looking forward to becoming part of it. Establishing our North American\n business and global commercial activities here is part of our strategic\n plan not only for the launch of MACRILENTM in the United States, as potentially the first FDA approved oral\n product for use in evaluating growth hormone deficiency in adults, but\n also for our future commercial opportunities. Furthermore, this marks\n an important milestone in Aeterna Zentaris' transition from an R&D\n company into a commercially operating company. As we evaluated our\n options, we were highly impressed by the commitment to life sciences\n demonstrated by the leadership of South Carolina and the emergence of\n Charleston as a collaborative center for research and development in\n the biopharmaceutical industry. We especially want to thank and\n acknowledge the leadership within the South Carolina Research\n Authority, the South Carolina Department of Commerce, the Charleston\n Regional Development Alliance and the team at the Medical University of\n South Carolina, all of whom contributed to this significant decision\n for our corporation. Finally, we wish to thank Governor Nikki Haley,\n who personally conveyed the state's commitment to assisting companies\n such as ...